Participated · Series B · Feb 2026

Kainova Therapeutics is a clinical-stage biopharmaceutical company focused on modulating G protein-coupled receptors (GPCRs) to improve patient outcomes in immuno-oncology and inflammation. The company’s lead program is a clinical-stage, Treg-depleting anti-CCR8 antibody that management says offers differentiated competitive features. A second program, currently at the pre-IND stage, is a first-in-class biased antagonist of PAR2 aimed at inflammatory pathways. By advancing these assets, Kainova seeks to build a diversified pipeline of GPCR-targeting therapies that can address multiple high-value indications. The firm operates across North America, France, and Australia, leveraging global clinical infrastructure. Proceeds from its recent Series B financing will be used to move its GPCR programs further into clinical development. No revenue, patient enrollment, or other operating metrics were disclosed, reflecting its pre-commercial status.

Participated · Seed · Jun 2025

OutSee applies a “genomics-first” strategy to drug target discovery through its proprietary Nomaly platform, which employs hypothesis-free AI modelling to predict disease and phenotype directly from individual genomes. By analysing fundamental molecular and cellular biology, Nomaly is able to reveal disease-driving mechanisms even in small or previously analysed datasets, making it complementary to conventional target-discovery pipelines. The company is building an internal portfolio of data-backed targets and has already identified a lead candidate that will advance into drug discovery with support from external partners. A recent strategic collaboration with o2h discovery will create a library of drug candidates against this lead target, leveraging o2h’s integrated pre-clinical CRO capabilities and co-discovery InflexionTx match-funding model. Proceeds from OutSee’s oversubscribed £2.5 million seed round will fund experimental validation of additional targets, expansion of its in-house discovery programme, and continued R&D to evolve Nomaly from validation phase to active value generation. The financing also underscores growing investor confidence in the company’s AI-powered approach to precision medicine.

Participated · Series B · Aug 2024

Human Longevity develops longevity-focused technologies and services centered on an artificial intelligence health risk and recommendation platform. It operates a 100+ Longevity Care membership program designed to identify early stages of major age-related diseases and to increase healthspan and lifespan via its clinical care team and data platform. The program leverages precision-medicine inputs including whole-genome sequencing, whole-body and brain MRI, comprehensive cardiac evaluations, body composition analysis, advanced blood biomarkers, and wearables. By continually adding and analyzing client health data, the company aims to shift care from reactive to proactive, preventative, and personalized. The company plans to invest in additional longevity technologies, services, and new expansion sites globally. Human Longevity is headquartered in San Francisco, CA. Human Longevity operates the Health Nucleus intelligence platform, which combines specialized imaging, whole genome sequencing and other lab tests with machine learning and AI to generate precision health analytics. The company provides in-depth Health Nucleus assessments in La Jolla, CA, delivering risk analyses for cardiac, cancer, metabolic and cognitive issues. Core inputs to the platform include whole genome sequencing, brain and body MRI, cardiac CT (CAT) scans, metabolic tests and additional diagnostics. Human Longevity positions these integrated metrics as a comprehensive standard for measuring health and performance for physicians and patients. The company announced a $30 million financing to support its operations. Proceeds from the financing will be used to enhance the Health Nucleus intelligence platform. Human Longevity, Inc. (HLI) is a San Diego, CA–based genomics company led by co-founder and CEO J. Craig Venter, Ph.D., that aggregates whole-genome, phenotype and clinical data. Its core offerings include the HLI Health Nucleus, a genomic-enhanced clinical research center that combines whole genome sequencing, advanced clinical imaging and machine learning. The company is developing large-scale computing and machine-learning approaches to discover novel insights in medicine. HLI operates the HLI Knowledgebase, which currently contains more than 20,000 complete genomes coupled with phenotype data. Its business also includes a Comprehensive Cancer Program and other sequencing programs. HLI plans to use new funding to grow and expand these products and continue development of the Knowledgebase.

Participated · Series A · Oct 2023

Actym Therapeutics has built the STACT (S. Typhimurium-Attenuated Cancer Therapy) platform, which uses a genetically modified bacterial vehicle to transport therapeutic payloads directly into the tumor microenvironment (TME). The company’s lead candidate, ACTM-838, delivers optimized IL-15 and STING payloads to the TME and has shown preferential enrichment and synergistic innate and adaptive anti-tumor responses in preclinical studies. STACT is positioned as a modular modality to achieve comprehensive immunological re-activation of immuno-compromised TMEs across multiple solid tumor indications. Actym plans to use the recent financing to enter a Phase 1 clinical trial designed to demonstrate proof of mechanism — selective tumor enrichment, payload delivery, and TME re-activation. The Phase 1 study will also assess dose selection, safety, efficacy, and pharmacokinetics of ACTM-838. Company commentary emphasizes translating its understanding of the TME into an effective and safe cancer therapy. Actym Therapeutics is a Berkeley, Calif.-based immuno-oncology company that has developed a microbial-based immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy). STACT selectively enriches in many types of solid tumors in preclinical studies and spares healthy tissue. Once localized to tumors, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. The platform is engineered to deliver payload combinations, enabling engagement of multiple biological pathways from a single therapy and addressing agents that are otherwise limited by systemic toxicities after IV dosing. The company completed a $34M Series A and will use the proceeds to advance STACT-derived immunotherapies into the clinic for the treatment of various cancers. Leadership includes CEO Christopher Thanos, Ph.D., VP Research Laura Hix Glickman, Ph.D., and Chief Medical Advisor Mark Frohlich, M.D.

Participated · Series A · Nov 2022

hC Bioscience engineers therapeutic tRNAs aimed at restoring protein function in diseases caused by nonsense mutations and premature termination codons (PTCs). Its lead platform is directed at precision protein editing to address genetically defined conditions, including oncology and inherited genetic diseases. The company says a single tRNA therapy could potentially treat many diseases regardless of the specific gene or mutation location. hC Bio plans to advance lead drug candidates by delivering tRNA both locally and systemically and to broaden its pipeline using the new financing. The company announced a $16 million extension to its Series A, bringing total Series A proceeds to $40 million, which it says will extend runway. hC Bioscience is based in Cambridge, Mass. hC Bioscience is a Cambridge, Mass.-based drug discovery company developing first-in-class tRNA-based therapeutics to correct protein dysfunction in genetically defined diseases. Its lead platform, PTCX ("Patch"), employs engineered tRNAs to suppress premature termination codons (PTCs) and restore full-length protein production, addressing nonsense mutations responsible for roughly 10–15% of human disease. A second platform, SWTX ("Switch"), is being developed to correct disease-causing missense mutations. The company emphasizes restoring protein function without editing genes and aims for single tRNA therapies that could treat many diseases regardless of the gene or mutation location. hC Bio was founded by Leslie J. Williams and Professor Christopher Ahern and has assembled a scientific advisory board including Nobel laureate Craig Mello; David Altreuter, Ph.D., was appointed CTO concurrent with the Series A close. The company closed a $24 million Series A to advance its pipeline and scientific program while pursuing partnerships with pharma and selected internal targets.